http://www.biolinktherapeutics.com/

BioLink Therapeutics, Machalandapur, Kalna, West Bengal (2026)

22/12/2025

📘 BioLink Therapeutics | 2025 Progress Report

Building an AI-Powered Discovery Platform from a Bootstrapped Foundation

BioLink Therapeutics was founded with a clear philosophy: build a robust, AI-driven drug discovery and a separate diagnostic platform first, then scale talent, partnerships, and impact around it. Fully bootstrapped since inception, BioLink has progressed by converting computational intelligence into real, executable pipelines addressing some of the most pressing challenges in global health.

🧠 AI-Powered Discovery Platform – The Core Engine

At the heart of BioLink Therapeutics lies a proprietary AI-powered discovery platform designed to integrate:

* Target biology and pathway intelligence
* Structure-based molecular design
* Small-molecule and mini-protein engineering
* Rapid in silico prioritization for translational readiness

🔬 Pipeline-Driven Innovation

1️⃣ Colon Cancer Screening Technology

BioLink’s diagnostic pipeline focuses on a biomarker-driven, non-invasive colon cancer screening technology designed for primary point-of-care deployment.

* Delivers actionable results within ~15 minutes
* Enables early detection without invasive procedures
* Built for scalability in resource-limited healthcare settings

This program represents a paradigm shift toward rapid, accessible, and data-driven cancer screening.

2️⃣ Antimicrobial Resistance (AMR) Pipeline

BioLink is addressing the global AMR crisis through AI-designed small molecules and mini-proteins that move beyond traditional antibiotic paradigms.

* AI-guided identification of novel chemical and peptide-like entities
* Focus on high-risk, drug-resistant pathogens
* Designed with resistance-evasion and selectivity in mind

This pipeline reflects BioLink’s commitment to next-generation anti-infective innovation.

3️⃣ Targeted Triple-Mutant Breast Cancer Program

A third core pipeline targets aggressive triple-mutant breast cancer, a subtype associated with limited treatment options and poor outcomes.

* AI-enabled target prioritization and molecular design
* Emphasis on precision, low toxicity, and translational relevance
* Built for combination-ready and biomarker-guided therapy

🤝 Collaboration Through Strategic Partnerships

To accelerate ex*****on, BioLink Therapeutics is actively engaging industry veterans to strengthen
* Drug discovery strategy
* Business development
* Collaboration with small-molecule synthesis partners under a risk–reward collaboration model, ensuring aligned incentives and shared success in pipeline advancement.

🌍 Global Online Industrial Internship Program – AI powered drug designing

The program trains students (Bachelor’s and Master's) and early-career scientists to:

* Apply AI tools directly to design your own drug molecules for human therapeutics.
* Learn structure-based drug design and molecular optimization
* Understand translational decision-making in biotech R&D

This initiative transforms BioLink’s platform into a living ecosystem—where innovation, education, and ex*****on converge. Our second batch will start in February'26. You can join our Q&A sessions in January'2026. Please write your interests through message at the website www.biolinktherapeutics.com

🔭 Looking Forward

BioLink Therapeutics is now transitioning from a fully bootstrapped builder phase to its
growth phase with priorities to:

* Advance pipelines toward preclinical milestones
* Expand strategic partnerships globally
* Strengthen leadership and advisory depth
* Prepare for structured capital infusion backed by real data

2025 stands as a defining year—where AI, science, and purpose align to shape BioLink Therapeutics into a globally relevant biotech innovation engine.

17/12/2025

Internship & Training on AI-Powered Drug Designing | BioLink Therapeutics

BioLink Therapeutics is actively bridging academic talent with real-world industrial training through its AI-powered drug design internship and training program. We have successfully developed 30+ hours of structured course modules, combining strong theoretical foundations with hands-on exposure to computational drug discovery and AI-driven pipelines.

The response has been truly global — we are receiving overwhelming interest and queries from students across France, Egypt, Sri Lanka, Pakistan, and India, highlighting the growing demand for applied AI skills in modern biotech and pharmaceutical R&D.

🎓 Eligibility:
Students currently pursuing or holding a Bachelor’s or Master’s degree in life sciences, biotechnology, bioinformatics, pharmacy, chemistry, computer science, or related disciplines are eligible to apply. PhD students and other professions are welcome.

🌐 Program Format:
The program is fully online, designed to be accessible globally, and offered at a minimal, affordable cost to ensure inclusivity while maintaining high-quality industrial exposure.

🚀 Stay tuned for upcoming live Q&A and interactive sessions in January, where we will address student questions, career pathways, and opportunities to work on real AI-driven drug discovery pipelines at BioLink Therapeutics.

Building skills. Bridging academia and industry. Creating future drug innovators.

Please reach out to us by messaging through the website www.biolinktherapeutics.com

14/12/2025

🚀 Progress Report & Strategic Announcement | BioLink Therapeutics

BioLink Therapeutics is proud to announce a major milestone in its journey toward building indigenous, high-impact healthcare innovations in India. Staying true to our mission of translating cutting-edge science into affordable, accessible diagnostics, we have entered a strategic collaborative partnership with Imgenex India Pvt. Ltd. to co-develop a biomarker-driven, non-invasive colon cancer screening kit for primary point-of-care use.

🧬 A First-of-Its-Kind Technology for India

This initiative represents a revolutionary advancement in cancer diagnostics in India. The proposed colon cancer screening kit will be the first biomarker-based, non-invasive diagnostic solution designed specifically for early detection at the primary care level. Unlike conventional approaches that rely on invasive procedures or centralized laboratory infrastructure, this technology aims to empower frontline healthcare settings with rapid, accurate, and affordable screening, enabling early clinical intervention and improved patient outcomes.

🤝 Collaborative Mission with Imgenex India Pvt. Ltd.

Imgenex India Pvt. Ltd., a well-established R&D-driven biotechnology company, brings deep expertise in assay development, biomarker validation, and translational research. Through this collaboration, BioLink Therapeutics and Imgenex share a unified mission:
to democratize cancer screening in India by integrating scientific rigor, industrial R&D capability, and real-world clinical relevance.

👨‍🔬 Strengthening the Scientific Core

As part of this expansion, BioLink Therapeutics has hired its first PhD-level Scientist, marking an important step in building our in-house translational research team. The scientist will be embedded at Imgenex’s R&D facility in Bhubaneswar, working closely with Imgenex scientists on assay optimization, biomarker validation, and early product development. This co-location model accelerates innovation, ensures seamless knowledge exchange, and reinforces our commitment to hands-on science.

🌍 Why This Matters

Colon cancer is a growing public health concern in India, yet routine screening remains limited due to cost, accessibility, and infrastructure gaps. A biomarker-driven, non-invasive point-of-care screening kit has the potential to transform early detection, particularly in semi-urban and rural settings, aligning perfectly with India’s preventive healthcare vision.

🔬 Looking Ahead

This collaboration lays the foundation for IDE-ready, clinically relevant cancer diagnostics developed and validated in India, for India and the world. BioLink Therapeutics remains committed to building strong academic-industry partnerships, nurturing scientific talent, and delivering original innovations beyond generics.

This is not just a product development milestone.
It is a step toward redefining how cancer is detected in India.

26/11/2025

🚀 BioLink Therapeutics Launches AI-Powered Drug Discovery Services for Academic Researchers

BioLink Therapeutics is proud to announce the advancement of our AI-powered drug discovery platform, designed to accelerate and democratize early-stage therapeutic innovation.

To strengthen scientific partnerships and validate the performance of our platform, we are now offering AI-driven drug-designing services to academic researchers at a nominal cost.
Our goal is simple: empower researchers with rapid, computation-backed molecule screening and design tools that can transform hypotheses into actionable therapeutic candidates.

🔬 Why BioLink?
Our platform integrates structure-based design, deep-learning–driven prediction models, and molecular optimization workflows to identify high-quality small-molecule leads. While we continue developing our internal pipelines in antimicrobial resistance (AMR) and cancer metastasis, we are equally committed to supporting the broader research community.

💡 An Invitation to Scientists & Innovators
If you are exploring new targets, testing therapeutic hypotheses, or seeking computational support for your research, BioLink Therapeutics is here to collaborate.

Advance your research with our validated, evolving, and purpose-built AI-powered drug designing platform.

📩 To collaborate or learn more, message us directly through website www.biolinktherapeutics.com

24/11/2025

⭐ Why Angel Investors Should Watch Early-Phase Startups Like BioLink Therapeutics

Angel investors look for early signs of resilience, ex*****on capacity, and scientific clarity - and BioLink Therapeutics stands exactly at that intersection. Startups that bootstrap their earliest milestones develop a level of discipline, efficiency, and strategic precision that funded startups often lack. BioLink has already demonstrated this rare combination:

✅ Secured a strategic collaboration with a reputed biotech company in India to advance a cancer detection technology toward IDE application - a milestone that typically requires significant early capital.

✅ Forged an academic collaboration with a leading IIT professor to validate AI-driven small-molecule designs against AMR, strengthening its preclinical therapeutics pipeline.

✅ Achieved acceptance into the prestigious C-CAMP Incubation Program, one of India's top biotech ecosystems, beginning November 1, 2025 - validation of scientific merit and innovation potential.

✅ Built a core scientific workforce, including hiring its first PhD Translational Scientist, entirely through bootstrapping.

These achievements signal a team capable of delivering high-value progress with minimal resources, reducing early-stage risk for investors.

For angel investors seeking ventures with strong scientific foundations, a diversified innovation pipeline, global health relevance, and founders who show unwavering grit, ex*****on power, and long-term strategic vision, BioLink Therapeutics is a startup that deserves early attention.
When such teams finally receive capital, they don’t experiment - they accelerate.

You may reach out to us by messaging through
website www.biolinktherapeutics.com

23/11/2025

A Call for Strategic Partners in Synthetic Chemistry: BioLink Therapeutics Is Building India’s First AI-Powered Drug Discovery Platform Against AMR

Antimicrobial resistance (AMR) is accelerating faster than the drugs we have to fight it. Globally, over 5 million deaths each year are linked to drug-resistant infections. India faces an even steeper challenge - treatment failures are rising, multidrug-resistant strains are spreading, and current antibiotics are rapidly losing effectiveness.

The unmet need is enormous.
The world urgently requires original drug discovery, especially from countries like India, where innovation must rise beyond the boundaries of generic drug production.

BioLink Therapeutics: Building India’s first AI-Powered Engine for New Molecules

At BioLink Therapeutics, we are developing an advanced AI-driven platform capable of designing novel, drug-like small molecules specifically against AMR mechanisms.

Our platform integrates:

* Predictive molecular modeling
* Structure–activity simulations
* Virtual screening of phytochemical derivatives and synthetic scaffolds
* ADMET and drug-likeness prediction
* Target-molecule interaction mapping

This ecosystem speeds up early discovery and produces high-confidence candidate molecules ready for synthesis and preclinical evaluation.

Strategic Scientific Partnerships With India’s Leading Institutes

To translate AI-designed molecules into validated therapeutic candidates, we have established collaborations with scientists from India’s premier institutions.

Together, we are building:

development pipelines
assays
vitro and early in vivo validation frameworks
-to-lab feedback loops for rapid optimization

But to accelerate the journey further, we need the right chemistry partners.

We Are Seeking Strategic Synthetic Chemistry Partners.

This message is specifically for companies with strong capabilities in:

✔ Small-molecule synthesis
✔ Scaffold modification
✔ Medicinal chemistry optimization
✔ Analytical characterization

We are actively looking for strategic collaborators who are passionate about co-developing first-in-class drug candidates against AMR.

India Must Lead in Original Drug Creation

India has built global reputation as the “pharmacy of the world,”
but the next era requires innovation, not replication.
Our mission is to position India as a creator of new molecular entities that address one of humanity’s greatest threats.

We invite chemistry-focused companies, CROs, pharma R&D teams, and research labs to collaborate with us and join this mission.

Let’s Co-Develop India’s Next Breakthrough Drugs

If you share this vision and can support synthetic chemistry capabilities, we would love to work with you.

👉 Please reach out through the message button on our website. www.biolinktherapeutics.com

Let’s unite our strengths, build novel molecules, and create life-saving therapies together.

17/11/2025

BioLink Therapeutics is attending a hands on workshop at C-CAMP, Bangalore from November 25 to November 28, 2025. This is not just another training program for us. It is a step forward in our mission to build affordable and impactful non invasive cancer diagnostic technologies for India.

https://lnkd.in/gjSSZaRS

Our founding team consists of PhD scientists with strong research depth and real world business development experience. With no seed fund we have already taken bold actions. We got incubated at C-CAMP. We signed an MOU with a reputed biotech company in India to co-develop and commercialize our cancer screening technology. We are moving with clarity focus and ex*****on discipline.

The workshop will train participants in device design microfabrication methods and assembly of lateral flow diagnostic kits through a complete learn by doing approach. For us it is an important opportunity. We aim to integrate these practical skills directly into our development pipeline. Our newly hired scientist, Dr. Priyobrata Sinha, will attend this workshop to enrich his skills.

By attending this program our goal is to sharpen our strategies to learn every technical detail needed and accelerate the creation of a functional prototype that can be validated with human samples for cancer detection.

Please connect us for business through message button within the website. We are open for angel investors.
www.biolinktherapeutics.com

16/11/2025

🌱 The Story of BioLink Therapeutics — Where We Stand and Where We’re Heading

Every startup has a moment when belief matters more than capital. For us at BioLink Therapeutics, that moment has defined our entire journey. We started with nothing but scientific clarity, conviction, and the courage to bootstrap our way forward.

Over the past months, we have quietly built momentum:

*We designed small molecules against AMR and cancer metastasis using our AI-powered drug discovery engine.
* We hired our first PhD translational scientist, strengthening our core research capability.
* We established a collaborative mission with a reputed biotech company in India to co-develop and validate our non-invasive cancer detection technology.
* We earned acceptance into C-CAMP Bangalore, gaining a scientific home for building our next-phase prototypes.

These milestones were not driven by funding - they were driven by discipline, strategic ex*****on, and the belief that meaningful science must start somewhere.

And now, as we enter the New Year, we are preparing for our next big leap.

BioLink Therapeutics is getting ready to reach out to angel investors, not for survival, but for expansion to raise seed capital that will allow us to initiate at least two IND-enabled studies. These studies will advance our AMR and oncology pipelines into real translational pathways.

We stand at the intersection of bootstrapping resilience and scientific ambition.
Our story is still being written but each milestone brings us closer to a future where affordable cancer diagnostics and novel therapeutics emerge from India to impact global health.

BioLink is advancing, the momentum is real, and the next chapter begins now.

Please reach out to us by messaging through website www.biolinktherapeutics.com

16/11/2025

BioLink Therapeutics Welcomes Its First PhD Translational Scientist: A Milestone in Our Bootstrapped Journey

BioLink Therapeutics is proud to announce a major milestone in its bootstrapped journey — the hiring of Dr. Priyobrata Sinha as our first PhD Translational Scientist. This marks a significant step forward as we move into prototype development and human sample validation for our affordable cancer screening technology.

Despite operating without external funding, BioLink has continued to advance its mission through determination, scientific rigor, and strategic partnerships. Our collaboration with Imgenex India accelerates the transition of our cancer screening platform from bench innovation to clinical readiness and Dr. Sinha will play a central role in this progress.

Dr. Sinha brings 10+ years of experience in molecular biology, biochemistry, assay development, PCR/qPCR, ELISA, Western blot, microscopy, cell culture, and animal handling. His background in translational research, scientific writing, problem-solving, mentoring, and critical thinking makes him an ideal fit for BioLink’s vision.

For a bootstrapped startup, hiring a full-time PhD scientist is more than a team expansion - it is a statement of BioLink’s long-term commitment to building affordable, accessible cancer diagnostics for India and bringing unmet solutions against antibacterial resistance and cancer metastasis.

With this milestone, BioLink Therapeutics continues to prove that innovation does not wait for funding - it moves forward with purpose, passion, and people who believe in the mission.

This is just the beginning.

01/11/2025

🚀 Mission in Motion | BioLink Therapeutics

From a vision shaped by translational research and entrepreneurial grit, BioLink Therapeutics continues to advance its mission — turning science into solutions for global health challenges.

Built entirely through bootstrapping, without any external seed funding, our journey reflects innovation powered by determination and purpose.

🌿 Our Recent Milestones
🔹 Partnered with a reputed biotech company in India (official media release coming soon) to advance our cancer detection technology toward IDE application — a significant step toward bringing biomarker-driven diagnostics to clinical reality.

🔹 Established an academic collaboration with an IIT professor (announcement forthcoming) to validate our AI-based drug discovery models and develop preclinical therapeutic interventions in antimicrobial resistance (AMR).
🔹 Accepted into the C-CAMP Incubation Program, Bangalore, beginning November 1,2025 marking the start of a new chapter.

🔹 Preparing to hire our first PhD Scientist, strengthening our translational research capabilities.

💡 Our Mission:
To accelerate AI-powered therapeutic and diagnostic innovations targeting AMR, neurodegeneration, and cancer, bridging the gap between academic discovery and industrial translation across India and the global biotech ecosystem.

Every step forward reaffirms our belief that impactful science can grow even without funding — when powered by vision, teamwork, and purpose.

Stay tuned — exciting updates ahead! 🌍✨

https://lnkd.in/eKHE9h9y
Email:therapeuticsbiolink@gmail.com

19/10/2025

🌟 Adjunct Instructor Position in Bioinformatics & Drug Discovery 🌟

Organization: BioLink Therapeutics LLP, INDIA
Program: Online Industrial Internship Program in Bioinformatics and Drug Discovery
Mode: Remote / Online

📢 About the Role
BioLink Therapeutics is seeking an Adjunct Instructor to lead and mentor students in our cutting-edge Online Industrial Internship Program, designed for Bachelor’s and Master’s students aspiring to enter the world of AI-driven drug discovery and computational biology.

This program bridges academic learning with real-world biotech applications, equipping students with skills in bioinformatics, molecular modeling, and AI-based drug design for therapeutic innovation.

👩‍🏫 Responsibilities
Deliver online training sessions in bioinformatics, molecular simulations, and computational drug discovery.

Mentor students on real-world projects and case studies.

Support development of research-driven modules that integrate academia with industrial applications.

🎓 Qualifications
PhD in Biophysics, Bioinformatics, or related field.

Strong background in computational biology, drug discovery, or related disciplines.

Prior teaching, mentoring, or industry experience preferred.

📬 How to Apply
Interested candidates are encouraged to email their CV and a brief statement of interest to:
📧 therapeuticsbiolink@gmail.com

BioLink Therapeutics

22/12/2025

17/12/2025

14/12/2025

26/11/2025

24/11/2025

23/11/2025

17/11/2025

16/11/2025

16/11/2025

01/11/2025

19/10/2025

Address

Website

Alerts

Contact The Practice

Shortcuts

Share